Key clinical point: Despite treatment with active salvage therapy, the prognosis of patients with diffuse large B-cell lymphoma (DLBCL) who relapse following hematopoietic stem cell transplant (HSCT) is poor.
Major finding: The median time to relapse after autologous HSCT was 7 months, with a 3-year overall survival rate of 27% and overall response rate of 46% post-salvage therapy.
Study details: A retrospective analysis of 256 patients with DLBCL who relapsed following auto-HSCT and received active salvage therapy. Data came from the European Society for Blood and Marrow Transplantation.
Disclosures: No funding sources were reported. The authors reported having no conflicts of interest.
González-Barca E et al. Bone Marrow Transplant. 2019 Sep 20. doi: 10.1038/s41409-019-0650-x.